Possible Sildenafil Use Against Prostate Cancer?

By Author: Kurt P. Smith
Total Articles: 24
Comment this article

There is no doubt that Generic Viagra is one of the most popular medications on the market. It has been developed in the late 1990s with the aim of helping men overcome one of the most common conditions that can affect them and their lovemaking lives as well as their sex lives: erectile dysfunction. Generic Viagra like Kamagra contains Sildenafil Citrate, a chemical compound that inhibits the action of the PDE-5 proteins improving in turn the blood circulation throughout the body. This enables men to attain harder and longer lasting erections simply because the penis receives the blood supply that it needs for a healthy erection.

Past research has constantly shown that Sildenafil Citrate is a good enhancer when it comes to the blood circulation. Specialists agree that this compound can improve the blood flow throughout the body and that it relieves some of the pressure that is put onto the cardiovascular system when the blood circulation is not as it should be. Previous research has encouraged specialists to check whether this medication could not be used in the treatment ...
... of many more conditions and not only for erectile dysfunction. As a result, studies have been carried out in order to see whether conditions such as pulmonary hypertension, muscular dystrophy and even Jetlag could be treated with Sildenafil.

Current research is carried out for possibilities of treatment of prostate cancer. Although Generic Viagra and Sildenafil Citrate are officially approved only to be used in the erectile dysfunction treatment, there are reasons to believe that it might be useful in the treatment of prostate cancer as well. It has been shown that while used together with a cancer drug, Doxorubicin, Sildenafil can be quite promising in the treatment of prostate cancer. Yet, these are only tests and the drug is not yet approved for this use. However, millions of men can enjoy its benefits when it comes to ED.